5 August 2024 - Patients requiring a 320 mg dose of bimekizumab will now have an alternative single injection option of both the pre-filled syringe and the pre-filled pen.

UCB today announced that the European Commission has granted marketing authorisation for two 320 mg device presentations of Bimzelz (bimekizumab). The pre-filled syringe and pre-filled pen each contain 320 mg of bimekizumab in a volume of 2 mL and provide alternatives to the currently available 160 mg/1 mL injection options.

Read UCB press release